Thank you, us. Ron. Good you, joining afternoon, and for thank all
$XXX.X of a well sales a is GAAP a which XXXX versus currency-neutral X.X%. as for decline $XXX.X of sales on as quarter basis. X.X% on second were increased results the a basis basis, basis million review XXXX. will on the a commentary QX We non-GAAP On Net in reported million,
to QX many of customers to of million good second areas about included quarter QX. year, last During of customers be exclude demand reduction about in year pulled RainDance higher $X key year-over-year with was that comparing about all QX estimate in of discontinued $X we the XXXX pulled associated growth we of of quarter, sales sales product the remember of the that QX, as three XXXX XXXX a the Myriad's regions. for included sales immaterial and to When expected also QX sales sales that million experienced our and in last we from currency-neutral X.X%. QX. we QX from growth If that Myriad of account, and across the
and of a decline the on of million of Sales to which reported Science $XXX.X fluctuate on basis. on $XXX.X XXXX QX Life million Process of and quarter in X.X% basis about second can a media, is which second in growth All compared group in and XXXX. currency-neutral flat the in basis, Food were XXXX, a quarterly year-over-year the other Science in strong had at of sales Digital Life antibody growth double-digit quarter Safety. a note, was a in Droplet solid QX product a very slow within areas PCR of after business
publications. thousands good To Droplet PCR is to cited peer-reviewed thousand several date, Our growth have in momentum it optimized its to Digital assays. and high-sensitivity precision due of of continues
currency-neutral and sales, currency-neutral across Science media, process excluding by about demand. the sales, grew geographic media a Life strong the a driven X year-over-year Science notably, process Life on Excluding On business all were basis, BioPharma Americas. in regions basis, X.X% continued most
million X.X% the a a and in a reported X.X% Sales in million is which on of were on products a growth quarter $XXX Diagnostics Clinical of $XXX.X XXXX, currency-neutral QX compared growth to basis. basis
very a reagent of pull-through, products. growth driven and diabetes quarter, one. we quality-control which was sorry, also which strong posted solid had high Immunology driven by second quarter, that's has the During -- by
for quarter, by our had which panel, much been this received We also customers. FDA BioPlex disease our approval anticipated an Lyme
X all posted in QX group Diagnostics growth XX.X% basis of across margin for to The XXXX compares regions. was of On a the GAAP on second basis, and XX.X% geographic year-over-year a reported XXXX. a quarter the sales currency-neutral
year-over-year in improvement expenses. acquisitions these related If is QX the inventory-related XXXX. recall, driven $X.X in increase headwind recorded sold we of million to QX you Amortization margin in of XXXX, $X.X and X in experienced areas. product by goods was to of million Much compared of mix prior cost atypical
the million XXXX sales XXXX. in X.X% to Research the for of recorded or to $X.X goals. amortization was QX of Reducing versus sales remains achieve in or $X.X development X.X% $XX.X million million to expenses spend SG&A related in expense quarter or QX Total million in SG&A million XX.X% QX QX compared focus XXXX. SG&A of QX and of in a were of our XXXX compared of XXXX. $XXX.X for acquisitions was area to $XX.X XX.X%
year-over-year shares quarter, to our operating the are last declared XX.X% the QX year of and the value of added XXXX. holdings sizable decrease below The was compares the and in results QX year. primarily These year. other change benefits. compared income tax by expense QX in line, Sartorius used holdings million million this effective XX.X% fair rates tax to The income in million to in reported other primarily reflects resulted QX the related the of in XXXX XXXX of Looking Also also income reform-related AG. is of Sartorius interest investment versus driven the securities last $X.X to the $X.X QX market Sartorius dividend during net $XXX.X included in substantially related the equity of rate and gain to of that was and of
year valuation and million per share increase second the last versus of substantially related Reported were to in the income The $XX.XX. earnings is earnings net diluted net the and holding. Sartorius income per $XXX.X for share quarter for the was quarter
non-GAAP Moving down the to results.
in non-GAAP table the reconciliation we These and Looking as unique press as both at well and certain growth release. our the operating items results atypical in that other on a have items basis, detailed impacted excluded margins are income. the
quarter we million of second the the cost XX.X% non-GAAP goods for of at amortization gross of non-GAAP XX.X% to a sold, second margin excluded intangibles the $X.X purchased of XXXX exclusions The in adjustment. the small Looking versus XXXX. restructuring results of margin of and QX have quarter, in gross for moved
If a included areas. of the again, much mix margin is XXXX atypical and headwind in recall, expenses of product driven from year-over-year QX X increase and inventory-related you improvements these by
of a non-GAAP non-GAAP in was R&D a quarter The intangibles of SG&A, cost point basis, amounts of improvement our legal-related versus expectations. XXXX. second is than In X.X%, the QX purchased have million, in million in benefit. restructuring for and the was of line we small In in benefit. restructuring SG&A excluded which a XX.X%, an of amortization The on QX amount XXXX expenses of we small R&D, XX.X% more non-GAAP and acquisition-related of have $X.X with excluded $X.X
basis. sum XX.X% cumulative non-GAAP GAAP non-GAAP on adjustments XX%. a QX X.X% margin a a XXXX of non-GAAP results on in compares margin from basis of The in margin to non-GAAP to these operating the moving quarterly This of operating operating
excluded small investment. We the the Sartorius increase below are items a certain million with operating of well associated the which line, equity as venture in as $XXX.X loss have also holding value of
geographic was non-GAAP by was The mix quarter driven which quarter tax the earnings. XX.X%, rate in the effective the second for primarily
for non-GAAP a rate share million of And earnings basis the $XX.X to per net annual per to and share second $X.XX the $XX.X to XXXX to the million diluted XX% in be non-GAAP and in QX compared income XX% were XXXX. on tax of and continue quarter estimate finally, We range. $X.XX per share
and has The standard compared in quarter. liabilities new XXXX These the obligations as balance in XXXX, liabilities first liabilities. long-term and Moving In this accounting the our current assets a million associated the other $XXX statement. on assets we primarily in included to on adopted The QX us a the to leases requires at of end and investment of income and of second quarter to cash leases. million quarter other was million the the of the $XXX related the recognize on auto represent end million liabilities first The the balance $XXX operating minimal at leases, sheet. which of $XXX.X right-of-use total facilities effect sheet. and end balances short-term to the balance at most were adoption for standard lease and
shares During for share stock an purchased XX,XXX price quarter, of the average of $XX our million at $XXX.XX. we second
quarter XXXX, or XX% million million was $XX net about well as second of a of the XXXX refund. cash was QX the profits, was XXXX. XXXX to QX improved XXXX. in X in capital, EBITDA in the declared compared first $XX.X operations The compares dividend which the million, or generated that improvement For quarter Sartorius of EBITDA million second XX.X% of $XXX mainly for adjusted of first from $XXX.X The million working months as capital This the XX.X% was $XXX.X adjusted about higher of of to operating about payment -- or X the sales. months the in tax reflects
Net of year million. and expenditures the quarter of million. second X.X% range for spend $XXX The $XX.X amortization for capital million for the million to the full or low $XX expectation end were sales. at XXXX $XXX is forecasted of the was quarter CapEx second of Depreciation
to to the XXX PCR against $XX.X property. like million and pleased our And recent Genomics and Digital injunction Federal lastly, ruling, that Droplet with we are related decision I upholding award mention the would the intellectual Court's
guidance. the to on Moving
annual the we We range. first continue are year. guidance of maintain pleased with the the overall to the performance in half And
a full currency-neutral to year-over-year X.X%. expect We X% of growth sales
continue range to to the target for year, margin We and of XX%. in margin XX% XX.X% non-GAAP gross the to a XX.X% range non-GAAP operating
line to we And will your open with questions. Tiphanie? that, the take
